No abstract

A double-blind, placebo-controlled trial was conducted to study the effects of over-the-counter analgesic/antipyretic medications on virus shedding, immune response, and clinical status in the common cold. Sixty healthy volunteers were challenged intranasally with rhinovirus type 2 and randomized to one of four treatment arms: aspirin, acetaminophen, ibuprofen, or placebo. Fifty-six volunteers were successfully infected and shed virus on at least 4 days after challenge. Virus shedding, antibody levels, clinical symptoms and signs, and blood leukocyte levels were carefully monitored. Use of aspirin and acetaminophen was associated with suppression of serum neutralizing antibody response (P less than .05 vs. placebo) and increased nasal symptoms and signs (P less than .05 vs. placebo). A concomitant rise in circulating monocytes suggested that the suppression of antibody response may be mediated through drug effects on monocytes and/or mononuclear phagocytes. There were no significant differences in viral shedding among the four groups, but a trend toward longer duration of virus shedding was observed in the aspirin and acetaminophen groups.

Responses from a sample of 400 older persons were used to determine the relative importance of various family members (spouse, children, siblings, other relatives) and friends in the confidant and companion networks of later life. Significant differences exist among older persons (based on gender, marital status, and availability of children) in the salience of these ties as confidants and companions. There are also major differences in the configuration of the confidant vs companion networks. These variations are discussed in the context of the hierarchical-compensation, task specificity, and functional specificity of relationships models of support. The findings demonstrate that a distinction regarding availability of kin must be made among those who never had a particular kin tie (e.g., the childless and single), those who have lost a previous tie (e.g., the widowed), and those whose tie lives far away.

No abstract

Drawing on the Women's Health Effects Study, a community sample of women (N = 309) who recently left an abusive partner, this study examines patterns of cumulative abuse experiences over the life course, their socioeconomic correlates, and associations with a range of health outcomes. Latent class analysis identified four groups of women with differing cumulative abuse profiles: Intimate Partner Violence (IPV) Dominant, Child Abuse and IPV, All Forms, and All Forms Extreme. We find a relationship pattern between cumulative abuse and socioeconomic circumstances, and significantly worse health outcomes among women with the All Forms Extreme profile. Implications for research and practice are discussed.

This study examines and compares the correlates of considering each of the following as a confidant or a companion: spouse, children, siblings, other relatives, friends. Using a Canadian sample of 400 respondents aged 65 and over, we found evidence of substitution among the previously married and childless; more extensive ties to children and more intimate ties to friends among women; the importance of geographic proximity to children for confiding and companionship, and to siblings for confiding; the relevance of family size to confiding in siblings; and the precariousness of friendship as one reaches very old age. Predictors of who serve as confidants and as companions are similar, but important differences emerge. We compared our results to those of studies in Australia and the United States and to an earlier analysis of network composition and concluded that the confiding and companionate relations of older persons are best understood by combining the results of relationship-specific and network composition analyses.

No abstract

In a double-blind evaluation of alpha 2-interferon as prophylaxis against naturally acquired respiratory infections, 120 adult members of 46 Australian families used 325 courses of intranasal spray during a six-month period, applying 5 million IU to the anterior nasal mucosa daily for seven days when respiratory symptoms developed in another member of the family. Used in this way, the alpha 2-interferon was well tolerated, and the rate of minor nasal bleeding (12 percent) did not increase with repeated courses. By comparison with the control group of 109 members of 49 families who used 319 seven-day courses of placebo spray, the users of alpha 2-interferon experienced 33 percent fewer days with nasal symptoms and 41 percent fewer episodes of "definite" respiratory illness. The users of alpha 2-interferon who were exposed to rhinovirus infections experienced 76 percent fewer days with symptoms and 86 percent fewer "definite" illnesses than their counterparts who used placebo. All of the observed clinical benefits, which suggested prevention of 6.8 "definite" respiratory illnesses per 100 courses of medication used, could be explained by a protective effect against illness associated with rhinoviruses that was not demonstrated for influenza A or B or coronavirus 229E.